Authors’ Reply to Cotton and Nicol’s Comment on “Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia”

Mark C, Simone N. Comment on: Adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia (letter). Drug Saf. 2015. doi:10.1007/s40264-015-0334-4. Joint United Nations Programme on HIV and AIDS (UNAIDS). Access to antiretroviral therapy in Africa. Geneva: UNAIDS; 2013. http://www.unaids.org/sites/default/files/media_asset/20131219_AccessARTAfricaStatusReportProgresstowards2015Targets_en_0.pdf. Accessed 20 July 2015. Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS ONE. 2014;9(5):e97353. doi:10.1371/journal.pone.0097353. Bezabhe WM, Bereznicki LR, Chalmers L, Gee P, Kassie DM, Bimirew MA, et al. Adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia. Drug Saf. 2015;38(7):629–39. doi:10.1007/s40264-015-0295-7. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460–5. doi:10.1097/QAI.0b013e3181f2ac87.